Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Biomerica ( (BMRA) ) has issued an update.
Biomerica, Inc. held its 2025 Annual Meeting of Stockholders on December 12, 2025, where several key proposals were voted on. The stockholders elected five nominees to the Board of Directors, approved executive compensation, ratified the selection of Haskell & White LLP as the independent accounting firm, and approved amendments to increase authorized shares and the stock incentive plan.
The most recent analyst rating on (BMRA) stock is a Sell with a $2.00 price target. To see the full list of analyst forecasts on Biomerica stock, see the BMRA Stock Forecast page.
Spark’s Take on BMRA Stock
According to Spark, TipRanks’ AI Analyst, BMRA is a Underperform.
Biomerica’s overall stock score is heavily impacted by its poor financial performance and valuation. The technical analysis further supports a bearish outlook, with the stock showing signs of being oversold. The absence of earnings call data and corporate events leaves these areas unaddressed, reinforcing the need for strategic improvements.
To see Spark’s full report on BMRA stock, click here.
More about Biomerica
Average Trading Volume: 94,558
Technical Sentiment Signal: Sell
Current Market Cap: $7.61M
For detailed information about BMRA stock, go to TipRanks’ Stock Analysis page.